Quetiapine
Clinical data | |
---|---|
Pronunciation | /kwɪˈtaɪ.əpiːn/ kwi-TY-ə-peen |
Trade names | Seroquel, Seroquel XR, Temprolide, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a698019 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Atypical antipsychotic |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 100%[4] |
Protein binding | 83%[5] |
Metabolism | Liver via CYP3A4-catalysed sulfoxidation to its active metabolite norquetiapine (N-desalkylquetiapine)[8] |
Elimination half-life | 7 hours (parent compound); 9–12 hours (active metabolite, norquetiapine)[5][6] |
Excretion | Kidney (73%), feces (20%)[4][5][6][7] |
Identifiers | |
| |
JSmol) | |
Solubility in water | 3.29 mg/mL (20 °C) |
| |
| |
(verify) |
Quetiapine, sold under the brand name Seroquel among others, is an atypical antipsychotic medication used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder.[9][10] Despite being widely used as a sleep aid due to its sedating effect, the benefits of such use may not outweigh its undesirable side effects.[11] It is taken orally.[9]
Common side effects include sleepiness,
Quetiapine was developed in 1985 and approved for medical use in the United States in 1997.
Medical uses
Quetiapine is primarily used to treat schizophrenia or bipolar disorder.[17] Quetiapine targets both positive and negative symptoms of schizophrenia.[18]
Schizophrenia
A 2013 Cochrane review compared quetiapine to typical antipsychotics:
Summary | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quetiapine may not differ from typical antipsychotics in the treatment of positive symptoms, general psychopathology, and negative symptoms. However, it causes fewer adverse effects in terms of abnormal ECG, extrapyramidal effects, abnormal prolactin levels and weight gain.[19] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
In a 2013 comparison of 15 antipsychotics in effectiveness in treating schizophrenia, quetiapine demonstrated standard effectiveness. It was 13–16% more effective than ziprasidone, chlorpromazine, and asenapine and approximately as effective as haloperidol and aripiprazole.[20]
There is tentative evidence of the benefit of quetiapine versus placebo in schizophrenia; however, definitive conclusions are not possible due to the high rate of attrition in trials (greater than 50%) and the lack of data on economic outcomes, social functioning, or quality of life.[21]
It is debatable whether, as a class,
A Cochrane review comparing quetiapine to other atypical antipsychotic agents tentatively concluded that it may be less efficacious than
Bipolar disorder
In those with
Major depressive disorder
Quetiapine is effective when used by itself[10] and when used along with other medications in major depressive disorder (MDD).[10][25] However, sedation is often an undesirable side effect.[10]
In the United States,[6] the United Kingdom[26] and Australia (while not subsidised by the Australian Pharmaceutical Benefits Scheme for treatment of MDD), quetiapine is licensed for use as an add-on treatment in MDD.[27]
Alzheimer's disease
Quetiapine does not decrease agitation among people with Alzheimer's disease. Quetiapine worsens intellectual functioning in the elderly with dementia and therefore is not recommended.[28]
Others
The use of low doses of quetiapine for
It is sometimes used
Quetiapine and clozapine are the most widely used medications for the treatment of Parkinson's disease psychosis due to their relatively low extrapyramidal side-effect liability.[44] Owing to the risks associated with clozapine (e.g. agranulocytosis, diabetes mellitus, etc.), clinicians often attempt treatment with quetiapine first, although the evidence to support quetiapine's use for this indication is significantly weaker than that of clozapine.[45][46]
Adverse effects
Sources for incidence lists:[4][6][26][27][46][47]
- Very common (>10% incidence) adverse effects
- Dry mouth
- Dizziness
- Headache
- Somnolence (drowsiness; of 15 antipsychotics quetiapine causes the 5th most sedation. Extended release (XR) formulations tend to produce less sedation, dose-by-dose, than the immediate release formulations.)[20]
- Common (1–10% incidence) adverse effects
- High blood pressure
- Orthostatic hypotension
- High pulse rate
- High blood cholesterol
- Elevated serum triglycerides
- Abdominal pain
- Constipation
- Increased appetite
- Vomiting
- Increased liver enzymes
- Backache
- Asthenia
- Insomnia
- Lethargy
- Tremor
- Agitation
- Nasal congestion
- Pharyngitis
- Fatigue
- Pain
- Dyspepsia(Indigestion)
- Peripheral oedema
- Dysphagia
- Weight gain: SMD 0.43 kg when compared to placebo. Produces roughly as much weight gain as risperidone, less weight gain than clozapine, olanzapine and zotepine and more weight gain than ziprasidone, lurasidone, aripiprazole and asenapine.[20] As with many other atypical antipsychotics, this action is likely due to its actions at the H1 histamine receptor and 5-HT2C receptor.[8]
- Rare (<1% incidence) adverse effects
- Prolonged QT interval (had an odds ratio for prolonging the QT interval over placebo of 0.17)[20]
- Sudden cardiac death
- Syncope
- Diabetic ketoacidosis
- Restless legs syndrome
- Hyponatraemia, low blood sodium.
- Jaundice, yellowing of the eyes, skin and mucous membranes due to an impaired ability of the body to clear bilirubin, a by product of haem breakdown.
- Pancreatitis, pancreas swelling.
- Agranulocytosis, a potentially fatal drop in white blood cell count.
- Leukopenia, a drop in white blood cell count, not as severe as agranulocytosis.
- Neutropenia, a drop in neutrophils, the cell of the immune cells that defends the body against bacterial infections.
- Eosinophilia
- Anaphylaxis, a potentially fatal allergic reaction.
- Seizure
- Hypothyroidism, underactive thyroid gland.
- Myocarditis, swelling of the myocardium.
- Cardiomyopathy
- Hepatitis, swelling of the liver.
- Suicidal ideation
- Priapism. A prolonged and painful erection.
- Stevens–Johnson syndrome. A potentially fatal skin reaction.
- Neuroleptic malignant syndrome a rare and potentially fatal complication of antipsychotic drug treatment. It is characterised by the following symptoms: tremor, rigidity, hyperthermia, tachycardia, mental status changes (e.g. confusion), etc.
- Tardive dyskinesia. A rare and often irreversible neurological condition characterised by involuntary movements of the face, tongue, lips and rest of the body. Most commonly occurs after prolonged treatment with antipsychotics. It is believed to be particularly uncommon with atypical antipsychotics, especially quetiapine and clozapine[27]
Both typical and atypical antipsychotics can cause tardive dyskinesia.[48] According to one study, rates are lower with the atypicals at 3.9% as opposed to the typicals at 5.5%.[48] Although quetiapine and clozapine are atypical antipsychotics, switching to these atypicals is an option to minimize symptoms of tardive dyskinesia caused by other atypicals.[49]
Weight gain can be a problem for some, with quetiapine causing more weight gain than
As with some other anti-psychotics, quetiapine may lower the seizure threshold,[51] and should be taken with caution in combination with drugs such as bupropion.
Discontinuation
The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse.[52] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite.[53] Other symptoms may include restlessness, increased sweating, and trouble sleeping.[53] Less commonly there may be a feeling of the world spinning, numbness, or muscle pains.[53] Symptoms generally resolve after a short period of time.[53]
There is tentative evidence that discontinuation of antipsychotics can result in psychosis.[54] It may also result in reoccurrence of the condition that is being treated.[55] Rarely tardive dyskinesia can occur when the medication is stopped.[53]
Pregnancy and lactation
Placental exposure is least for quetiapine compared to other atypical antipsychotics.[46] The evidence is insufficient to rule out any risk to the foetus but available data suggests it is unlikely to result in any major foetal malformations.[5][7][47] It is secreted in breast milk and hence quetiapine-treated mothers are advised not to breastfeed.[5][7][47]
Abuse potential
In contrast to most other antipsychotic drugs, which tend to be somewhat aversive and often show problems with patient compliance with prescribed medication regimes, quetiapine is sometimes associated with drug misuse and abuse potential, for its hypnotic and sedative effects. It has a limited potential for misuse, usually only in individuals with a history of polysubstance abuse and/or mental illness, and especially in those incarcerated in prisons or secure psychiatric facilities where access to alternative intoxicants is more limited. To a significantly greater extent than other atypical antipsychotic drugs, quetiapine was found to be associated with drug-seeking behaviors, and to have standardised street prices and slang terms associated with it, either by itself or in combination with other drugs (such as "Q-ball" for the intravenous injection of quetiapine mixed with cocaine). The pharmacological basis for this distinction from other second generation antipsychotic drugs is unclear, though it has been suggested that quetiapine's comparatively lower dopamine receptor affinity and strong antihistamine activity might mean it could be regarded as more similar to sedating antihistamines in this context. While these issues have not been regarded as sufficient cause for placing quetiapine under increased legal controls, prescribers have been urged to show caution when prescribing quetiapine to individuals with characteristics that might place them at increased risk for drug misuse.[56][57][58][59][60]
Overdose
Most instances of acute overdosage result in only sedation, hypotension and tachycardia, but cardiac arrhythmia, coma and death have occurred in adults. Serum or plasma quetiapine concentrations are usually in the 1–10 mg/L range in overdose survivors, while postmortem blood levels of 10–25 mg/L are generally observed in fatal cases.[61] Non-toxic levels in postmortem blood extend to around 0.8 mg/kg, but toxic levels in postmortem blood can begin at 0.35 mg/kg.[62][63]
Pharmacology
Pharmacodynamics
Site | QTP | NQTP | Action | Ref |
---|---|---|---|---|
SERT | >10,000 | 927 | Blocker | [65] |
NET | >10,000 | 58 | Blocker | [65] |
DAT | >10,000 | >10,000 | ND | [65] |
5-HT1A | 320–432 | 45 | Partial agonist | [65][66] |
5-HT1B | 1,109–2,050 | 1,117 | ND | [65][66] |
5-HT1D | >10,000 | 249 | ND | [65][66] |
5-HT1E | 1,250–2,402 | 97 | ND | [65][66] |
5-HT1F | 2,240 | ND | ND | [66] |
5-HT2A | 96–101 | 48 | Antagonist | [65][66] |
5-HT2B | ND | 14 | Antagonist | [65] |
5-HT2C | 2,502 | 107 | Antagonist | [65] |
5-HT3 | >10,000 | 394 | Antagonist | [65] |
5-HT4 | ND | ND | ND | ND |
5-HT5A | 3,120 | 768 | ND | [65] |
5-HT6 | 1,865 | 503 | Antagonist | [65] |
5-HT7 | 307 | 76 | Antagonist | [65] |
α1A | 22 | 144 | Antagonist | [65] |
α1B | 39 | 95 | Antagonist | [65] |
α2A | 2,230–3,630 | 237 | Antagonist | [65][66] |
α2B | 90–747 | 378 | Antagonist | [65][66] |
α2C | 28.7–350 | 736 | Antagonist | [65][66] |
β1 | >10,000 | >10,000 | ND | [65][66] |
β2 | >10,000 | >10,000 | ND | [65][66] |
D1 |
712 | 214 | Antagonist | [65] |
D2 |
245 | 196 | Antagonist | [65] |
D2L |
700 | ND | Antagonist | [66] |
D2S |
390 | ND | Antagonist | [66] |
D3 |
340–483 | 567 | Antagonist | [65][66] |
D4 |
1,202 | 1,297 | Antagonist | [65] |
D4.2 |
1,600 | ND | Antagonist | [66] |
D5 |
1,738 | 1,419 | Antagonist | [65] |
H1 | 2.2–11 | 3.5 | Antagonist | [65] |
H2 | >10,000 | 298 | Antagonist | [65] |
H3 | >10,000 | >10,000 | ND | [65] |
H4 | >10,000 | 1,660 | ND | [65] |
M1 | 858 | 39 | Antagonist | [65] |
M2 | 1,339 | 453 | ND | [65] |
M3 | >10,000 | 23 | Antagonist | [65] |
M4 | 542 | 110 | ND | [65] |
M5 | 1,942 | 23 | Antagonist | [65] |
σ1 | 220–3,651 | >10,000 | ND | [65][66] |
σ2 | 1,344 | 1,050 | ND | [65] |
NMDA (PCP) |
>10,000 | ND | Antagonist | [65] |
VDCC |
>10,000 | ND | ND | [65][66] |
hERG |
ND | >10,000 ( IC50 ) |
ND | [65] |
Values are Ki (nM), unless otherwise noted. The smaller the value, the more strongly the drug binds to the site. All data are for human cloned proteins, except σ1 (guinea pig), σ2 (rat), and VDCC (rat).[65][66] |
Quetiapine has the following pharmacological actions:[67][68][69][70][71][72][73][74]
- antagonist
- Serotonin 5-HT1A receptor partial agonist, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT6, and 5-HT7 receptor antagonist, and 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F receptor ligand
- α1- and α2-adrenergic receptor antagonist
- H1 receptor antagonist
- antagonist
This means quetiapine is a
At very low doses, quetiapine acts primarily as a histamine receptor blocker (antihistamine) and α1-adrenergic blocker. When the dose is increased, quetiapine activates the adrenergic system and binds strongly to serotonin receptors and autoreceptors. At high doses, quetiapine starts blocking significant amounts of dopamine receptors.[68][79] Due to the drug's sedating H1 activity, it is often prescribed at low doses for insomnia. While some feel that low doses of drugs with antihistamine effects like quetiapine and mirtazapine are safer than drugs associated with physical dependency or other risk factors, concern has been raised by some professionals that off-label prescribing has become too widespread due to underappreciated hazards.[80]
When treating schizophrenia, antagonism of D2 receptor by quetiapine in the mesolimbic pathway relieves positive symptoms and antagonism of the 5-HT2A receptor in the frontal cortex of the brain may relieve negative symptoms and reduce severity of psychotic episodes.[18][81][82] Quetiapine has fewer extrapyramidal side effects and is less likely to cause hyperprolactinemia when compared to other drugs used to treat schizophrenia, so is used as a first line treatment.[83][84]
Pharmacokinetics
Peak levels of quetiapine occur 1.5 hours after a dose.
Chemistry
Quetiapine is a
, and other tetracyclic antipsychotics.Synthesis
The synthesis of quetiapine begins with a dibenzothiazepinone. The lactam is first treated with phosphoryl chloride to produce a dibenzothiazepine. A nucleophilic substitution is used to introduce the sidechain.[86]
History
Sustained-release
AstraZeneca submitted a
On 18 May 2007, AstraZeneca announced that the U.S. FDA approved Seroquel XR for acute treatment of schizophrenia.[89] During its 2007 Q2 earnings conference, AstraZeneca announced plans to launch Seroquel XR in the U.S. during August 2007.[90] However, Seroquel XR has become available in U.S. pharmacies only after the FDA approved Seroquel XR for use as maintenance treatment for schizophrenia, in addition to acute treatment of the illness, on 16 November 2007.[91] The company has not provided a reason for the delay of Seroquel XR's launch.
Health Canada approved sale of Seroquel XR on 27 September 2007.[92]
In early October 2008, the FDA approved Seroquel XR for the treatment of bipolar depression and bipolar mania. According to AstraZeneca, Seroquel XR is "the first medication approved by the FDA for the once-daily acute treatment of both depressive and manic episodes associated with bipolar."
On 31 July 2008, Handa Pharmaceuticals, based in Fremont, California, announced that its abbreviated new drug application ("ANDA") for quetiapine fumarate extended-release tablets, the generic version of AstraZeneca's SEROQUEL XR, has been accepted by the FDA.
On 1 December 2008, Biovail announced that the FDA had accepted the company's ANDA to market its own version of sustained-release quetiapine.[93] Biovail's sustained-release tablets will compete with AstraZeneca's Seroquel XR.
On 24 December 2008, AstraZeneca notified shareholders that the FDA had asked for additional information on the company's application to expand the use of sustained-release quetiapine for treatment of depression.[94]
Society and culture
Regulatory status
In the United States, the Food and Drug Administration (FDA) has approved quetiapine for the treatment of schizophrenia and of acute manic episodes associated with bipolar disorder (bipolar mania) and for treatment of bipolar depression.[95] In 2009, quetiapine XR was approved as adjunctive treatment of major depressive disorder.[96]
Quetiapine received its initial indication from U.S. FDA for treatment of schizophrenia in 1997.[97] In 2004, it received its second indication for the treatment of mania-associated bipolar disorder.[98] In 2007 and 2008, studies were conducted on quetiapine's efficacy in treating generalized anxiety disorder and major depression.
Patent protection for the product ended in 2012; however, in a number of regions, the long-acting version remained under patent until 2017.[99]
Lawsuits
In April 2010, the U. S. Department of Justice fined Astra-Zeneca $520 million for the company's aggressive marketing of Seroquel for off-label uses.[95] According to the Department of Justice, "the company recruited doctors to serve as authors of articles that were ghostwritten by medical literature companies and about studies the doctors in question did not conduct. AstraZeneca then used those studies and articles as the basis for promotional messages about unapproved uses of Seroquel."[95]
Multiple lawsuits have been filed in relation to quetiapine's side-effects, in particular, diabetes.[100][101][102][103]
Approximately 10,000[104] lawsuits[105] have been filed against AstraZeneca, alleging that quetiapine caused problems ranging from slurred speech and chronic insomnia to deaths.
Controversy
In 2004, a young man named Dan Markingson committed suicide in a controversial Seroquel clinical trial at the University of Minnesota while under an involuntary commitment order.[106] A group of University of Minnesota bioethicists charged that the trial involved an alarming number of ethical violations.[107]
Nurofen Plus tampering case
In August 2011, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued a class-4 drug alert following reports that some batches of Nurofen plus contained Seroquel XL tablets instead.[108]
Following the issue of the Class-4 Drug Alert, Reckitt Benckiser (UK) Ltd received further reports of rogue blister strips in cartons of two additional batches of Nurofen Plus tablets. One of the new batches contained Seroquel XL 50 mg tablets and one contained the Pfizer product
Following discussions with the MHRA's Defective Medicines Report Centre (DMRC), Reckitt Benckiser (UK) Ltd decided to recall all remaining unexpired stock of Nurofen Plus tablets in any pack size, leading to a Class-1 Drug Alert.[109] The contamination was later traced to in-store tampering by a customer.[110]
References
- FDA. Retrieved 22 October 2023.
- ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
- ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
- ^ a b c "quetiapine (Rx) - Seroquel, Seroquel XR". Medscape Reference. WebMD. Archived from the original on 20 October 2013. Retrieved 11 October 2013.
- ^ a b c d e f g "Quetiapine 25 mg film-coated tablets - Summary of Product Characteristics". electronic Medicines Compendium. Sandoz. January 2013. Archived from the original on 20 October 2013. Retrieved 20 October 2013.
- ^ a b c d e f Truven Health Analytics, Inc. DrugPoint System (Internet) [cited 2013 Sep 18]. Greenwood Village, CO: Thomsen Healthcare; 2013.
- ^ a b c "Quetiapine fumarate tablet". DailyMed. Ascend Laboratories, LLC. October 2013. Archived from the original on 2 December 2013. Retrieved 26 November 2013.
- ^ ISBN 978-0071624428.
- ^ a b c d e f g h "Quetiapine Fumarate". The American Society of Health-System Pharmacists. Archived from the original on 29 August 2017. Retrieved 26 March 2017.
- ^ PMID 21154393.
- S2CID 207292819. Archived from the original(PDF) on 19 February 2020.
- PMID 19300555.
- ISBN 978-0857112989.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Quetiapine - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "quetiapine-fumarate". The American Society of Health-System Pharmacists. Archived from the original on 10 February 2011. Retrieved 3 April 2011.
- ^ PMID 11051217.
- ^ from the original on 21 April 2016.
- ^ S2CID 32085212.
- ^ PMID 15106155.
- PMID 20954430.
- PMID 17619525.
- PMID 24249315.
- PMID 23554581.
- ^ ISBN 9780857110848.
- ^ ISBN 978-0-9805790-9-3.
- PMID 15722369.
- ^ S2CID 9888209.
- ^ PMID 24534594.
- PMID 33941603.
- PMID 22132426.
- PMID 22973576.
- S2CID 9888209.
- S2CID 250536370.
- S2CID 207263320.
- PMID 31860457.
- S2CID 230507941.
- PMID 36073694.
- .
- PMID 14642017.
- ^ Oliver Sacks "Musicophilia" Knopf NY 2007 P.67
- S2CID 34246401.
- S2CID 219168745.
In clinical practice, quetiapine is more readily used than clozapine, given its improved side effect profile compared to clozapine. Despite frequent use in clinical practice, its efficacy in PDP is less clear. ... The quetiapine evidence base is thus ambiguous, lacking consistent support from RCTs in PDP. In DLB there is reliance upon retrospective studies, with the inherent limitations therein. As with clozapine, sedation and orthostasis can be limiting factors. In clinical practice, despite the paucity of consistent evidence, quetiapine has been the first line antipsychotic therapy due to its side effect profile and lower neuroleptic sensitivity risk.
- PMID 21179595.
- ^ ISBN 9780470979693.
- ^ a b c "PRODUCT INFORMATION STADA(TM) Quetiapine (quetiapine fumarate Tablets 25 mg, 100 mg, 200 mg, 300 mg)". TGA eBusiness Services. STADA Pharmaceuticals Australia Pty Limited. 30 November 2012. Archived from the original on 27 March 2017. Retrieved 19 September 2013.
- ^ S2CID 37288246.
- S2CID 24308129.
- S2CID 38635470.
- ^ "Seroquel Prescribing Information". www.astrazeneca-us.com.
- ISBN 978-0-85369-845-6.
Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.
- ^ ISBN 9780198527480.
- S2CID 6267180.
- ISBN 9788847026797.
- PMID 28210359.
- PMID 28331860.
- S2CID 3292900.
- PMID 31068753.
- S2CID 203621793.
- ^ Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 1355–1357.
- PMID 25342720.
- PMID 26159868.
- ^ Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
- ^ PMID 18059438.
- ^ S2CID 12028979.
- ^ AstraZeneca. "Seroquel (quietapine fumarate) tablets" (PDF). Www1.astrazeneca-us.com. 276521. Archived from the original (PDF) on 14 April 2008.
- ^ PMID 11132243.
- ISBN 978-0-7817-2837-9.
- ^ "Seroquel Official FDA information, side effects and uses". Drugs.com. Archived from the original on 4 June 2012. Retrieved 9 July 2012.
- ^ AstraZeneca Pharmaceuticals LP (March 2011). "SEROQUEL (quetiapine fumarate) tablet, extended release". DailyMed. National Library of Medicine. Section 12.2: Pharmacodynamics. Retrieved 26 April 2011.
- ^ National Institute of Mental Health. PDSD Ki Database (Internet) [cited 2013 Sep 18]. Chapel Hill (NC): University of North Carolina. 1998-2013. Available from: "...list shows the top 100 Receptors/Targets in Ki". Archived from the original on 8 November 2013. Retrieved 5 July 2013.
- PMID 18059438.
- PMID 24062697.
- S2CID 11448976.
- ^ Guzman F. "Mechanism of action of quetiapine". Psychopharmacology Institute. Archived from the original on 11 August 2013. Retrieved 20 January 2013.
- PMID 11229973.
- PMID 11873706.
- S2CID 29460397.
- ^ "Drug Use Evaluation: Low Dose Quetiapine (Seroquel/Seroquel XR)" (PDF). Government Executive Media Group. Oregon State. Archived (PDF) from the original on 22 April 2016. Retrieved 20 January 2016.
- ^ a b "Quetiapine". www.drugbank.ca. Retrieved 23 January 2019.
- ^ "Seroquel" (PDF). FDA. Retrieved 23 January 2019.
- PMID 12562141.
- S2CID 22978385.
- ^ a b c d "Seroquel" (PDF). FDA. Retrieved 23 January 2019.
- ^ Warawa, E. J.; Migler, B. M.; 1988, U.S. patent 4,879,288.
- ^ "AstraZeneca Submits an NDA For Sustained Release Formulation Seroquel XR. For the treatment of schizophrenia" (Press release). AstraZeneca. 18 July 2006. Archived from the original on 5 November 2006. Retrieved 1 January 2007.
- ^ "AstraZeneca Submits EU and Canadian Regulatory Filings for Sustained Release Formulation SEROQUEL XR for the Treatment of Schizophrenia" (Press release). AstraZeneca. 19 October 2006. Archived from the original on 7 November 2006. Retrieved 1 January 2007.
- ^ "FDA Approves AstraZeneca's Once-Daily SEROQUEL XR Extended-Release Tablets For The Treatment Of Schizophrenia" (Press release). AstraZeneca. 18 May 2007. Archived from the original on 28 September 2007. Retrieved 2 August 2007.
- ^ "Second Quarter and Half Year Results 2007" (Press release). AstraZeneca. 26 July 2007. Archived from the original on 24 August 2007. Retrieved 2 August 2007.
- ^ "Seroquel XR Receives Approval from FDA for Maintenance Treatment of Schizophrenia" (Press release). AstraZeneca. 16 November 2007. Archived from the original on 4 December 2007. Retrieved 3 December 2007.
- ^ Notice of Compliance Information - Seroquel XR[permanent dead link] 27 September 2007, retrieved 3 December 2007
- ^ "Biovail Announces Filing of ANDA for Quetiapine XR Tablets" (Press release). Biovail. 1 December 2008. Archived from the original on 9 August 2007.
- ^ "AstraZeneca Receives FDA Complete Response Letter on Seroquel XR for Major Depressive Disorder" (Press release). AstraZeneca. 24 December 2008. Archived from the original on 26 October 2010. Retrieved 28 December 2008.
- ^ a b c "Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-label Drug Marketing". Justice news, US Department of Justice. 27 April 2010. Archived from the original on 13 July 2012. Retrieved 16 July 2012.
- ^ Guzman F. "Quetiapine Indications: FDA-Approved and Off-label Uses". Psychopharmacology Institute. Archived from the original on 22 January 2014. Retrieved 19 January 2013.
- ^ "QUETIAPINE FUMARATE". Electronic Orange Book. Food and Drug Administration. April 2007. Archived from the original on 5 January 2009. Retrieved 24 May 2007.
- ^ "AstraZeneca Receives FDA Approval for SEROQUEL in Bipolar Mania" (Press release). AstraZeneca. 13 January 2004. Archived from the original on 8 June 2011.
- ^ AstraZeneca (2013). "Pioneering science, life-changing medicines". www.sec.gov. Archived from the original on 6 March 2016. Retrieved 26 March 2017.
- ^ Knef A (2 August 2007). "Seroquel suit claims 'so much' is poured into marketing and away from research". The Madison / St. Clair Record. Archived from the original on 21 August 2008.
- ^ Milford P (11 March 2009). "AstraZeneca May Link Seroquel, Diabetes, Doctor Says". Bloomberg.com. Bloomberg L.P. Archived from the original on 24 September 2015.
- ^ "AstraZeneca wins bellwether Seroquel case". FiercePharma. 19 March 2010. Archived from the original on 14 March 2012. Retrieved 9 July 2012.
- ^ "AstraZeneca pays out million dollar damages". The Local. 9 August 2010. Archived from the original on 17 August 2010.
- ^ "Questions loom over drug for sleepless vets - Marine Corps News | News from Afghanistan & Iraq". Marine Corps Times. Archived from the original on 2 June 2013. Retrieved 9 July 2012.
- ^ Wilson D (19 July 2011). "Heart Warning Added to Label on Popular Antipsychotic Drug". NyTimes. Archived from the original on 2 July 2012. Retrieved 9 July 2012.
- ^ Elliott C (September–October 2010). "The Deadly Corruption of Clinical Trials". Mother Jones. Archived from the original on 17 November 2012. Retrieved 2 December 2012.
- ^ Couzin-Frankel J (7 December 2010). "Minnesota bioethicists critique their university". Science. Archived from the original on 21 February 2013. Retrieved 2 December 2012.
- ^ "Press release, 25 August 2011" (Press release). MHRA. Archived from the original on 19 March 2012. Retrieved 9 July 2012.
- ^ "Drug Alerts". MHRA. Archived from the original on 19 March 2012. Retrieved 9 July 2012.
- ^ "Nurofen Plus tampering: Christopher McGuire jailed". BBC News. 28 May 2012. Archived from the original on 14 June 2012. Retrieved 9 July 2012.